181,886 Shares in Medpace Holdings, Inc. $MEDP Purchased by Norges Bank

Norges Bank bought a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 181,886 shares of the company’s stock, valued at approximately $102,156,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. BOKF NA increased its stake in Medpace by 0.8% in the 3rd quarter. BOKF NA now owns 2,542 shares of the company’s stock valued at $1,307,000 after buying an additional 20 shares during the last quarter. Valeo Financial Advisors LLC increased its stake in Medpace by 5.0% in the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock valued at $249,000 after buying an additional 21 shares during the last quarter. HighPoint Advisor Group LLC increased its stake in Medpace by 2.8% in the 3rd quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock valued at $416,000 after buying an additional 22 shares during the last quarter. Kaufman Rossin Wealth LLC increased its stake in Medpace by 3.4% in the 4th quarter. Kaufman Rossin Wealth LLC now owns 795 shares of the company’s stock valued at $447,000 after buying an additional 26 shares during the last quarter. Finally, Berkeley Inc increased its stake in Medpace by 1.0% in the 4th quarter. Berkeley Inc now owns 2,694 shares of the company’s stock valued at $1,513,000 after buying an additional 27 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Trending Headlines about Medpace

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Rosen, Pomerantz, Schall, Faruqi & Faruqi, and others, reiterated that a class action has been filed against Medpace alleging violations of federal securities laws and investor harm. Article Title
• Negative Sentiment: The lawsuits center on purchases made between April 22, 2025 and February 9, 2026, with investors urged to act before the June 8 lead-plaintiff deadline, keeping legal risk and uncertainty in focus. Article Title
• Neutral Sentiment: One item noted a management change, with Medpace elevating Brad Hansman to an executive operations role, but this appears to be a routine corporate update with no immediate market-moving detail. Article Title

Analysts Set New Price Targets

MEDP has been the subject of several analyst reports. Leerink Partners decreased their price objective on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research note on Wednesday, February 11th. Robert W. Baird decreased their price objective on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Royal Bank Of Canada decreased their price objective on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and reduced their target price for the company from $462.00 to $419.00 in a research report on Wednesday, February 18th. Finally, Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price for the company in a research report on Friday, February 13th. Four research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $467.08.

Insider Buying and Selling

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the transaction, the president directly owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. This trade represents a 67.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 20.50% of the stock is owned by corporate insiders.

Medpace Stock Down 1.0%

Medpace stock opened at $454.25 on Friday. Medpace Holdings, Inc. has a twelve month low of $294.07 and a twelve month high of $628.92. The firm has a 50 day moving average price of $456.73 and a 200-day moving average price of $508.93. The company has a market capitalization of $12.97 billion, a P/E ratio of 28.55, a P/E/G ratio of 2.33 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The firm had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. During the same period in the prior year, the firm earned $3.67 EPS. The company’s revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities analysts expect that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.